Date: 2012-09-26
Type of information: Services contract
Compound: PLX cells - PLacental eXpanded (PLX) cells
Company: Pluristem Therapeutics (Israel) Fisher BioServices (USA)
Therapeutic area:
Type agreement:
Action mechanism: The PLX cells are mesenchymal-like adherent stromal cells (ASCs) derived from full term placenta. The cells are expanded in the company\'s proprietary bioreactor system, which provides a three dimensional (3D) microenvironment that enables full control over the manufacturing process, large-scale growth of these cells and batch to batch consistency. PLX cells are immune privileged and possess immunomodulatory properties.
Disease:
Details: Pluristem Therapeutics, a leading developer of placenta-based cell therapies, has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacental eXpanded (PLX) cells. Fisher BioServices will provide cryogenic storage and distribution of Pluristem’s PLX cells for its clinical trials and preclinical sites around the world.
Pluristem currently is targeting several therapeutics indications for which clinical trials and preclinical studies are in progress, which include: a) intermittent claudication; b) muscle regeneration c) critical limb ischemia d) Buerger’s disease; and e) acute radiation syndrome. The different studies are scheduled to take place in Europe, India, Israel and the U.S. In addition, Pluristem has reported strong pre-clinical study results in other indications for which the company may pursue clinical trials in the future. These include the treatment of acute myocardial infarction (heart attack), lung disease, and bone marrow disease.
Fisher BioServices is the world\'s leading provider of specialized biological sample and material management, and cell therapy logistics services to pharmaceutical and biotech companies, and national, state and academic institutions. Equipped to provide storage and cold chain transportation capabilities for the entire spectrum of cell-based and regenerative medicine worldwide, Fisher BioServices also provides distribution of cell-based therapies from manufacturer to patient bedside, with complete chain of custody documentation.
Financial terms:
Latest news:
